Advanz Begins Appeal Of £100M CMA Drug Pricing Fine
Pharmaceutical company Advanz and its two former private equity owners said Tuesday that a £100 million ($107 million) fine levied by the competition watchdog for charging the NHS too much for...To view the full article, register now.
Already a subscriber? Click here to view full article